Optimal management of elderly patients with myeloma
Chiara Cerrato1, Roberto Mina, Antonio Palumbo
1Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy.
Abstract:
Many advances have been made in the treatment of patients with multiple myeloma including elderly subjects. The introduction of novel agents, such as thalidomide, lenalidomide, bortezomib, have revolutionized the treatment paradigm of this neoplasm, and second-generation molecules are currently being tested to offer patients a wider variety of treatment options and to improve outcome. The efficacy of a regimen should be carefully balanced against its toxicity profile. Elderly patients are particularly susceptible to adverse events that may lead to early treatment discontinuation. Thus, a more accurate distinction within the elderly population and a more appropriate treatment allocation is necessary. Here we describe the major and more recent treatment options available today for elderly patients with multiple myeloma.
Insights
Novel agents have transformed multiple myeloma treatment, especially for elderly patients. Balancing efficacy and toxicity is key for this vulnerable population, necessitating tailored treatment strategies.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Background:
- Multiple myeloma treatment has advanced significantly with novel agents.
- Elderly patients present unique challenges due to increased susceptibility to adverse events.
- Current treatment strategies require careful consideration of efficacy versus toxicity.
Purpose of the Study:
- To review recent and major treatment options for elderly patients with multiple myeloma.
- To highlight the need for personalized treatment allocation in this demographic.
- To discuss the evolving therapeutic landscape for older adults with multiple myeloma.
Main Methods:
- Literature review of recent clinical trials and treatment guidelines.
- Analysis of efficacy and toxicity profiles of novel agents in elderly populations.
- Discussion of risk stratification and treatment selection criteria.
Main Results:
- Novel agents (thalidomide, lenalidomide, bortezomib) have improved outcomes.
- Second-generation agents are under investigation to expand treatment options.
- Careful management of toxicity is crucial to prevent treatment discontinuation in the elderly.
Conclusions:
- Treatment paradigms for multiple myeloma have been revolutionized by novel agents.
- Personalized treatment approaches are essential for elderly patients, balancing efficacy and tolerability.
- Ongoing research aims to further refine therapeutic strategies for improved outcomes in older adults.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
01:22Myocarditis IV: Nursing Management
01:24Nephrotic Syndrome III : Nursing Management
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:25Peritoneal Dialysis III: Nursing Management
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...